Researcher
Christophe Deroose
- Disciplines:Medical imaging and therapy, Medicinal products
Affiliations
- Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Oct 2002 → Today
Projects
1 - 10 of 28
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom2 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- Targeted alpha therapy of pancreatic tumors in a theranostic settingFrom1 Oct 2022 → TodayFunding: BOF - projects, Fund Recuperation Fiscal Exemption
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- 18F-PSMA-1007 PET/MR imaging, quantification and radiomics in the primary staging of prostate cancer and response prediction after neoadjuvant hormonal therapyFrom1 Aug 2021 → TodayFunding: FWO fellowships
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Tb-IRMA-V: Terbium ISOL radioisotopes for medical applications in FlandersFrom1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research (SBO)
- Development of theranostic somatostatin analogues for the treatment of neuroendocrine tumorsFrom1 Oct 2018 → 15 Dec 2022Funding: SCK (Study Centre Nuclear Energy)
Publications
1 - 10 of 208
- Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.(2023)
Authors: Christophe Deroose, Ann Smeets
Pages: e331 - e343 - Radioligand therapies in cancer: mapping the educational landscape in Europe(2023)
Authors: Hendrik Van Poppel, Christophe Deroose
Pages: 2692 - 2698 - 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use(2023)
Authors: Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Frederik Cleeren, Christophe Deroose
Pages: 835 - 841 - Prospective comparison of [F-18]AlF-NOTA-octreotide PET/MRI to [Ga-68]Ga-DOTATATE PET/CT in neuroendocrine tumor patients(2023)
Authors: Frederik Cleeren, Jeroen Dekervel, Michel Koole, Guy Bormans, Paul Clement, Kristiaan Nackaerts, Koenraad Van Laere, Christophe Deroose
- Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer(2023)
Authors: Christophe Deroose, Karolien Goffin
- Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study(2023)
Authors: Christophe Deroose, Annouschka Laenen, Dietmar Rudolf Thal, Oliver Bechter, Paul Clement
Pages: 480 - 487 - 18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/ NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study(2023)
Authors: Elin Pauwels, Frederik Cleeren, Michel Koole, Jeroen Dekervel, Annouschka Laenen, Paul Clement, Eric Van Cutsem, Chris Verslype, Guy Bormans, Christophe Deroose
Pages: 632 - 638 - Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist(2023)
Authors: Stephen Ahenkorah, Christopher Cawthorne, Christophe Deroose, Thomas Cardinaels, Guy Bormans, Frederik Cleeren
- [F-18] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [I-123] MIBG in neural crest tumour patients(2023)
Authors: Sofie Celen, Kristof Baete, Michel Koole, Oliver Bechter, Paul Clement, Koenraad Van Laere, Guy Bormans, Christophe Deroose
Pages: 1134 - 1145 - Effect of sleeve gastrectomy and Roux-en-Y gastric bypass on gastrointestinal physiology(2023)
Authors: Nele Steenackers, Tim Vanuytsel, Patrick Augustijns, Christophe Deroose, Gwen Falony, Matthias Lannoo, Ann Mertens, Roman Vangoitsenhoven, Lucas Wauters, Bart Van Der Schueren, et al.
Pages: 92 - 101